EXPLORINEER
en

Archive — US — techcrunch

Converge Bio raises $25M, backed by Bessemer and execs from Meta, OpenAI, Wiz

Converge Bio, a Boston and Tel Aviv-based startup, has raised $25M to enhance drug development using generative AI. Led by Bessemer Venture Partners and backed by execs from Meta and OpenAI, the funding enables their AI-driven platform to streamline the drug development lifecycle, supporting pharma and biotech firms in faster, data-driven research. The startup seeks to reshape drug discovery amid growing competition in AI integration.

Key points

  • Converge Bio raised $25M in an oversubscribed Series A round led by Bessemer Venture Partners.
  • The startup develops AI tools for drug discovery by training models on molecular data to improve R&D efficiency.
  • They have rolled out three systems: antibody design, protein yield optimization, and biomarker target discovery.
  • With 40 partnerships and 40 active programs, Converge's tools have significantly boosted protein yields and produced high-affinity antibodies.
  • The company's rapid growth includes increasing their team from 9 to 34 employees in under two years.
  • Converge aims to be the generative AI lab for life sciences, partnering wet labs with computational solutions.

Why it matters

  • The surge in AI in drug discovery parallels a broader technology trend where AI enhances R&D efficiency across sectors.
  • Historically, AI adoption in pharmaceuticals has been slow but picked up pace as success stories emerge.
  • The recent Nobel Prize awarded for advancements in protein structure prediction (AlphaFold) demonstrates AI's transformative impact in life sciences.
  • Converge's growth reflects the increasing investment and shift from traditional trial-and-error approaches to data-driven strategies in drug development.

Converge Bio is at the forefront of AI-driven drug discovery, addressing the urgent need for efficiency in pharma R&D through innovative generative models. With increased funding and strategic growth, the startup demonstrates the significant potential of AI to reshape the pharmaceutical landscape.